Effect of peginterferon alfa-2a (40 KD) (PEGASYS) on viral response in patients with HBeAg-positive chronic hepatitis B.
Phase of Trial: Phase IV
Latest Information Update: 19 Nov 2015
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Roche
- 23 Feb 2010 Actual initiation date (Nov 2003) added as reported by Roche record.
- 10 Jan 2008 New trial record.